Charles River Laboratories CRL

Charles River Laboratories (CRL) has reported strong Q1 2026 results, with sales of $995.8 million and a non-GAAP profit of $2.06 per share, exceeding market expectations. However, the company faces challenges with a 1.5% year-on-year decline in organic revenue, leading to pressures on profit margins. In light of its performance, CRL has raised its full-year adjusted EPS guidance to $11.05 at the midpoint and signed a significant MOU with MEDIPOST to enhance GMP testing solutions. Despite recent achievements, CRL remains cautious about future revenue prospects following long-term declines in organic growth.